orexigen

FDA declines to approve Orexigen diet drug (AP)

AP – Orexigen Therapeutics Inc. said Tuesday that U.S. health officials rejected its experimental weight loss pill Contrave and requested a new study of its potential heart risks, suggesting it will be years before a new drug for obesity reaches the market.

See the rest here:
FDA declines to approve Orexigen diet drug
(AP)

orexigen

FDA rejects Orexigen’s weight-loss drug Contrave (AFP)

AFP – The US Food and Drug Administration on Tuesday declined to approve a weight loss drug by the California pharmaceutical company Orexigen, saying it must conduct more studies to rule out heart risks.

Original post: 
FDA rejects Orexigen’s weight-loss drug Contrave
(AFP)

orexigen

U.S. rejects Orexigen diet drug over heart risks (Reuters)

Reuters – U.S. health regulators rejected Orexigen Therapeutics Inc’s weight-loss drug and requested a clinical trial to resolve heart safety concerns, dealing a huge blow to what stood to be the first new diet pill in a decade.

See original here: 
U.S. rejects Orexigen diet drug over heart risks
(Reuters)

orexigen

U.S. advisers back first new diet pill in a decade (Reuters)

Reuters – The first new weight-loss pill in a decade moved closer to U.S. approval on Tuesday, when a panel of expert advisers backed Orexigen Therapeutics’s Contrave despite heart risk concerns.

Original post: 
U.S. advisers back first new diet pill in a decade
(Reuters)

orexigen

US panel approves first obesity drug in a decade (AFP)

AFP – An advisory panel to the US Food and Drug Administration on Tuesday gave its approval to an anti-obesity drug, in what could be the first new approved drug for losing weight in more than a decade.

Read more here: 
US panel approves first obesity drug in a decade
(AFP)

orexigen

New Diet Pill Wins FDA Panel’s Backing (HealthDay)

HealthDay – TUESDAY, Dec. 7 (HealthDay News) — An expert advisory panel recommended on Tuesday that Contrave, a new weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the U.S. Food and Drug Administration.

See the original post: 
New Diet Pill Wins FDA Panel’s Backing
(HealthDay)

orexigen

FDA panel recommends approval for Contrave (AP)

AP – A Food and Drug Administration panel on Tuesday recommended that the agency approve Orexigen Therapeutics Inc.’s weight loss drug Contrave, making it the first in group of competitors to get a positive nod from experts.

View post: 
FDA panel recommends approval for Contrave
(AP)

orexigen

Orexigen diet pill faces U.S. panel, eyes on safety (Reuters)

Reuters – The last of a trio of new weight loss drugs, Orexigen Therapeutics Inc’s Contrave, is set to face a panel of U.S. advisers on Tuesday who are likely to have tough questions on the pill’s heart risks and other safety concerns.

See the rest here:
Orexigen diet pill faces U.S. panel, eyes on safety
(Reuters)

orexigen

FDA scrutinizes weight loss pill from Orexigen (AP)

AP – Scientists for the Food and Drug Administration said Friday a pill to treat obesity from Orexigen Therapeutics Inc. helped patients lose weight, though it didn’t meet all the criteria set forth by the agency.

View original here: 
FDA scrutinizes weight loss pill from Orexigen
(AP)

orexigen

Obese patients lose weight on new Orexigen drug (Reuters)

Reuters – Overweight volunteers who took Orexigen’s experimental drug Contrave, designed to reduce cravings, lost about 13 pounds (6 kg) over a year, U.S. researchers reported on Thursday.

Read more from the original source:
Obese patients lose weight on new Orexigen drug
(Reuters)

Next Page »